Preliminary applications will only be accepted until January 18, 2016. If you plan to submit a PAR-15-297 grant application this cycle, an approved preliminary grant application is required. Please note that this has changed from previous application cycles.

Information is available regarding the PLCO trial and PLCO biospecimens.

Please visit the PAR Preliminary Application for Biospecimens and Funding page to preview instructions about the process, review the EEMS Policies and Procedures, and begin a PAR Preliminary Application for Biospecimens and Funding.

Due to administrative factors, the timeline for this review cycle may be subject to change. If you have any questions, please contact CDAS staff at cdas-eems@imsweb.com.

CDAS has been redesigned to incorporate an improved user interface and several new features. Start a new project or click on My Projects in the upper right corner to see a list of the projects you already have access to. Contact Us if you have any questions navigating the new site.

Preliminary applications for PLCO EEMS Round 21 will only be accepted from approximately December 1, 2015, through January 3, 2016. If you plan to submit an EEMS application this cycle, an approved preliminary application is required. Please note that this has changed from previous application cycles. Once your preliminary application has been approved, you will be notified and you will be able to continue and submit a full application. The deadline for full application submission is March 1, 2016.

Information is available regarding the PLCO trial and biospecimens.

Due to administrative factors and uncertainty in website development, the timeline for the release of the preliminary application and upcoming review cycle will be subject to changes. Please check CDAS frequently for an updated timeline. If you have any questions, please contact CDAS staff at cdas-eems@imsweb.com.

Preliminary applications will only be accepted from approximately December 1, 2015, through January 18, 2016.If you plan to submit a grant application this cycle, an approved preliminary grant application is required. Please note that this has changed from previous application cycles. Once your preliminary grant application has been approved, you will receive a confirmation letter to accompany your grant application.

Information is available regarding the PLCO trial and biospecimens.

Due to administrative factors and uncertainty in website development, the timeline for the release of the preliminary application and upcoming review cycle will be subject to changes. Please check CDAS frequently for an updated timeline. If you have any questions, please contact CDAS staff at cdas-eems@imsweb.com.

Data on non-lung cancer and AJCC 7 lung cancer stage have been added to the NLST datasets.

For all non-lung cancers diagnosed during NLST, the ICD-O-3 code and timing of diagnosis (days from randomization) are now available in the participant dataset.

For all lung cancers diagnosed during NLST, the overall AJCC 7 stage has been added to the participant dataset, and more detailed AJCC 7 information (pathologic and clinical TNM components) is in the lung cancer dataset.

All previously available data remain available and essentially unchanged. No datasets, variables, or records were deleted. A few existing variables had their values change.

• In the progression dataset, the "site" variables were corrected so that every instance of lung cancer progression has data on the site of progression. Previously, some instances of progression had all site variables set to “No”, which was incorrect.
• In the participant dataset, values were corrected (from “No” to “Missing”) for some baseline variables (work history, disease history). These changes should be inconsequential for most analyses. They affected fewer than 1000 participants, and no single variable changed for more than 202 participants.

New NLST lung cancer staging data added:

• Lung Cancer Diagnosis

New NLST non-long cancer data added:

• Non-lung Cancer Diagnosis